ctDNA Positivity More Frequent Less Than 6 Months from Treatment in TNBC
The phase 3 ZEST trial discovered that, with low ctDNA at baseline, the recurrence-free interval is longer for patients with triple-negative breast cancer.
Highlighting Advocacy Impacts on Funding for Kidney Cancer Research
Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.
Niraparib/Dostarlimab/Chemo Improves PFS Vs SOC in Advanced Ovarian Cancer
Niraparib/dostarlimab with platinum-therapy met its PFS end point in patients with advanced ovarian cancer in the phase 3 FIRST-ENGOT-OV44 trial.
Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors
Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.
Nab-Paclitaxel Combo Improves Response vs SOC in HER2+ Breast Cancer
Nab-paclitaxel elicited a pathologic complete response rate of 66.3% compared with 57.6% with docetaxel plus carboplatin, the phase 3 HELEN-006 trial found.
NX-5948 Earns Fast Track Designation in R/R Waldenström Macroglobulinemia
Results from a phase 1a trial showed that NX-5948 yielded an overall response rate of 77.8% in later lines of treatment for patients with WM.
